Growth Hormone Therapy for Wasting in Cystic Fibrosis
Status:
Terminated
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
Our hypothesis is that Growth Hormone (GH) will not only target the peripheral tissue to
stimulate weight and muscle growth which will maximize nutritional potential and improve
overall quality of life. We theorize that this will occur through a multitude of factors:
increased appetite, more constructive utilization of caloric intake and decreased catabolic
signaling. The first aim will address changes in weight and lean body mass following the
institution of GH therapy in adults with Cystic Fibrosis (CF) related wasting. The second aim
will measure impact on quality of life of these individuals. Additionally, the third aim will
monitor effects of GH therapy on diabetes and insulin sensitivity. Finally, the fourth aim
will observe changes in the subjects underlying diagnosis of CF, specifically lung function,
muscle strength and inflammatory state.